{'fraction_non_alphanumeric': 0.01971830985915493, 'fraction_numerical': 0.018309859154929577, 'mean_word_length': 5.405405405405405, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Effectiveness of intravenous infusion of ethmozin in patients with chronic ventricular arrhythmias].

Intravenous ethmozin in a dose of 270-730 mg for 4 h had pronounced antiarrhythmic effect in 80% of patients with frequent ventricular extrasystoles. In 10-14% of patients it may have arrhythmogenic effect. Positive correlation between duration and degree of the antiarrhythmic effect and dose and plasma ethmozin concentration was found. The character of the effect (antiarrhythmic or arrhythmogenic) did not depend on the dose and concentration of the drug. The indicated doses of intravenous ethmozin produce no serious side effect and may be recommended for treatment of chronic ventricular arrhythmias.